Shots:

• The P-III CREAD-1 and 2 study involves assessing of Crenezumab vs PBO in 1500 patients with early AD with confirmed evidence of cerebral beta-amyloid pathology (CSF or amyloid PET) for a duration of two years
• The discontinuation process of trial is based on its unmet 1EPs results from baseline Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score with no new safety signals observed
• Crenezumab is a mAb promotes removal of neurotoxic oligomers targeted for Alzheimer disease in Alzheimer’s Prevention Initiative (API) trial. Additionally- Roche is assessing Gantenerumab- an IgG1 mAb indicated for lowering amyloid plaque in AD patients

 Ref: Roche | Image: Roche